Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. - Wikidata - awgldk - TriplyDB

Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers.

Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers.

http://www.wikidata.org/entity/Q37264931

about

Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature Evidence from a meta-analysis: is nivolumabneurotoxic in cancer patients?Immunogenomics: using genomics to personalize cancer immunotherapy.Safety and efficacy of nivolumab in the treatment of cancers: A meta-analysis of 27 prospective clinical trials.Ocular toxicity due to Trametinib and Dabrafenib.Immune checkpoint inhibitors in advanced non-small cell lung cancer.Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients.The benefit and risk of nivolumab in non-small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized controlled trials.

P2860

Q37584406-79B6D85D-20C9-4CCE-8812-B4172DBFC323 Q37682801-F3252AFB-57D8-460A-ADF6-CD02B3719ADD Q38772744-2BD252CC-E77D-4797-8460-24E6B258A48A Q39215902-A4E34676-18B1-4AB7-BFEF-C60DE74F077B Q41451479-AA4078E3-3987-4A08-BD64-B357BECB22B2 Q47563451-A80CB7EE-D96F-442F-9686-31527FFBC432 Q52758918-F7202C03-050F-44D2-9D7E-385398BEA95C Q53835314-20FDDCB5-0047-4DA2-BDF7-0C04E291B506

P2860

Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers.

http://www.wikidata.org/entity/Q37264931

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 02 May 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Nivolumab, anti-programmed dea ...... apy: Role in advanced cancers.

@en

Nivolumab, anti-programmed dea ...... apy: Role in advanced cancers.

@nl

type

label

Nivolumab, anti-programmed dea ...... apy: Role in advanced cancers.

@en

Nivolumab, anti-programmed dea ...... apy: Role in advanced cancers.

@nl

prefLabel

Nivolumab, anti-programmed dea ...... apy: Role in advanced cancers.

@en

Nivolumab, anti-programmed dea ...... apy: Role in advanced cancers.

@nl

P1433

Q37264931-8FFCEBE3-C90A-4BDB-8258-C98E90622999

P1476

Q37264931-EF9954FB-5C08-4F0F-8775-1B2D9390E74E

P2093

Q37264931-789B1BED-8B4D-4136-9E3A-9884D3FA4A21

Q37264931-78D0B08F-1529-4D18-AC49-DBC6079C02DC

Q37264931-BBB12F82-E046-4F68-8DEE-54E2A25DFD82

Q37264931-D9A767E9-74BB-4BA0-9035-77546DFBF938

Q37264931-FA5AC3E3-856D-4F1A-ABFC-D254EFD472CD

P2860

Q37264931-0114643D-1EAF-43FE-9C5B-6BE34EEE021D

Q37264931-09632D7B-9B20-49D1-9C60-7B5439BDD995

Q37264931-12A299E9-E13B-4995-ADDB-1BDD1FF4A8AC

Q37264931-233B96CA-FC41-4657-8E64-8A8EFC68E0C1

Q37264931-248A2743-9DD8-492C-AE04-B1D0CF4FCA15

Q37264931-26C3DD0D-91DF-4BE3-8835-3D771D0BCABE

Q37264931-276C2DD4-E35F-4E38-B606-FF4AB87F14F8

Q37264931-27CA81E0-DC66-465D-9D8A-CE4F438A54D2

Q37264931-2AC41837-E004-4519-8ED7-ADC8331836E7

Q37264931-309BE879-B371-4F72-97CE-E2BD1588029F

P304

Q37264931-136D5218-0EF8-43ED-A61B-4EBC2CA46277

P31

Q37264931-17fd0a54-5d3d-4824-8ae9-314ea6fa5a1b

Q37264931-D979E64B-0213-4AEA-8448-495E4ACE5D52

P356

Q37264931-B11809FA-EB49-4A3D-864A-6645717F6E58

P433

Q37264931-2A610052-A0B7-4357-A62E-3D30BE7C7900

P478

Q37264931-C1602613-0466-4622-840E-C3ED7187750E

P577

Q37264931-6A0A6A93-BF3C-49F8-ADEF-0BC26EE8068B

P698

Q37264931-A41F1E7D-D4FC-4F22-A83B-406219CFEA48

P921

Q37264931-5CEDCDFF-3813-4AC0-B8A3-74DB4A4D0D0C

Q37264931-DFE8B946-91A7-48AC-9E94-D001E35D4E98

P932

Q37264931-BEF570F6-A8D7-47FF-9A50-E66EBF6914CE

P356

21645515.2016.1175694

P1433

Human Vaccines & Immunotherapeutics

P1476

Nivolumab, anti-programmed dea ...... apy: Role in advanced cancers.

@en

P2093

Arun Rajan

http://www.w3.org/2001/XMLSchema#string

Christopher R Heery

http://www.w3.org/2001/XMLSchema#string

Chul Kim

http://www.w3.org/2001/XMLSchema#string

James L Gulley

http://www.w3.org/2001/XMLSchema#string

Udayan Guha

http://www.w3.org/2001/XMLSchema#string

P2860

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment

Combining radiotherapy and cancer immunotherapy: a paradigm shift

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Ceritinib in ALK-rearranged non-small-cell lung cancer.

Improved overall survival in melanoma with combined dabrafenib and trametinib.

P304

2219-2231

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/21645515.2016.1175694

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27135835

http://www.w3.org/2001/XMLSchema#string

P921

P932

5027703

http://www.w3.org/2001/XMLSchema#string